Biotechnology – Oncology – Immunology – CNS

The potential offered by modern biotechnology is far from exhausted. Recombinant proteins, in paricular, continue to gain in significance.

Our generic line of oncological pharmaceuticals satisfies modern requirements. Our portfolio includes selected substances for different forms of cancer.

Despite considerable success in the battle against HIV infection, the nuber of anti-AIDS drugs is growing continuously. In the field of new drug development we are constantly searching for active ingredients that will facilitate more effective therapies. The focus of our efforts is an Highly Active Anti-Retroviral Therapy (HAART) and innovative substances that promise further advances in the medication of AIDS.

We offer the pharmaceuticals industry a broad and innovative product portfolio for the CNS API segment.

Print this page